I think this is one tool in our tool box. It's one step and one part of a continuum of care.
As others have mentioned, I don't think this is a debate of harm reduction versus recovery-oriented models. I think we need a full spectrum of different options. In a time when we're dealing with a progressively more toxic and unpredictable drug supply, we need more options to deal with these challenges, not fewer.